Valneva begins production of its COVID-19 vaccine
pharmafile | January 28, 2021 | News story | | COVID-19, Valneva
Valneva, a specialty vaccine company focused on the prevention of infectious diseases with significant unmet medical needs, has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate alongside ongoing clinical studies.
Production has begun in order to optimise the timeline for potential deliveries of the vaccine, and the Phase I/II clinical study is now fully enrolled, with initial results expected in April of this year.
Valneva’s jab, VLA2001, is currently the only inactivated vaccine candidate in clinical trials against coronavirus in Europe. A total of 150 healthy adults aged between 18 and 55 have been recruited for the Phase I/II study, which commenced in mid-December 2020.
Thomas Lingelbach, CEO of Valneva, said: “We are extremely pleased to have achieved these two important milestones in such a short period of time. Our team in Scotland have done an amazing job to get manufacturing started so quickly.
“I would like to thank the UK Vaccines Taskforce and National Institute for Health Research who have played vital roles in the rapid recruitment and enrollment of the volunteers for the clinical study. We believe that our vaccine, assuming successful development, can make a major contribution in the UK and beyond.”
In September last year, Valneva announced a major COVID-19 vaccine partnership with the UK government for the supply of up to 190 million doses of VLA2001. Under the agreement, if vaccine development is successful, the company will provide the UK government with 60 million doses in the second half of this year.
Valneva also announced in January that it is in advanced discussions with the European Commission for the supply of up to 60 million doses of its vaccine.
Darcy Jimenez
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
